Front-line therapy of advanced ovarian cancer: new approaches-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Front-line therapy of advanced ovarian cancer: new approaches

Published:2017-11 Issue: Volume:28 Page:viii46-viii50
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Ledermann J.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/suppl_8/viii46/22295163/mdx452.pdf

Reference25 articles.

1. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup;Bookman;J Clin oncol,2009

2. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N Engl J Med,2011

3. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N Engl J Med,2011

4. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial;Oza;Lancet Oncol,2015

5. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial;Rouzier;Eur J Cancer,2017

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In situ tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity to treat ovarian cancer and metastases;Acta Pharmaceutica Sinica B;2024-09

2. Enhancing carboplatin sensitivity in ovarian cancer cells by blocking the mercapturic acid pathway transporter;Carcinogenesis;2024-07-25

3. MAP7 drives EMT and cisplatin resistance in ovarian cancer via wnt/β-catenin signaling;Heliyon;2024-05

4. SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation;Communications Biology;2024-01-09

5. Pain nursing for gynecologic cancer patients;Frontiers in Oncology;2023-07-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3